317 related articles for article (PubMed ID: 31428048)
1. Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer.
Renaud CO; Ziros PG; Chartoumpekis DV; Bongiovanni M; Sykiotis GP
Front Endocrinol (Lausanne); 2019; 10():510. PubMed ID: 31428048
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells.
Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517
[TBL] [Abstract][Full Text] [Related]
3. Mice Hypomorphic for
Ziros PG; Renaud CO; Chartoumpekis DV; Bongiovanni M; Habeos IG; Liao XH; Refetoff S; Kopp PA; Brix K; Sykiotis GP
Thyroid; 2021 Jan; 31(1):23-35. PubMed ID: 32689903
[No Abstract] [Full Text] [Related]
4. The Keap1/Nrf2 Signaling Pathway in the Thyroid-2020 Update.
Thanas C; Ziros PG; Chartoumpekis DV; Renaud CO; Sykiotis GP
Antioxidants (Basel); 2020 Nov; 9(11):. PubMed ID: 33158045
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of Keap1/Nrf2 signaling in the thyroid gland and perspectives for bench-to-bedside translation.
Chartoumpekis DV; Ziros PG; Habeos IG; Sykiotis GP
Free Radic Biol Med; 2022 Sep; 190():276-283. PubMed ID: 35988853
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Keap1-Nrf2 signaling: The role of epigenetics.
Cheng D; Wu R; Guo Y; Kong AN
Curr Opin Toxicol; 2016 Dec; 1():134-138. PubMed ID: 29057383
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Keap1/Nrf2 stress response pathway in autophagic vacuolar myopathies.
Duleh S; Wang X; Komirenko A; Margeta M
Acta Neuropathol Commun; 2016 Oct; 4(1):115. PubMed ID: 27799074
[TBL] [Abstract][Full Text] [Related]
9. Insights into the New Cancer Therapy through Redox Homeostasis and Metabolic Shifts.
Hyun DH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32645959
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
12. Impact of Antioxidant Natural Compounds on the Thyroid Gland and Implication of the Keap1/Nrf2 Signaling Pathway.
Paunkov A; Chartoumpekis DV; Ziros PG; Chondrogianni N; Kensler TW; Sykiotis GP
Curr Pharm Des; 2019; 25(16):1828-1846. PubMed ID: 31267862
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.
Zhang S; Duan S; Xie Z; Bao W; Xu B; Yang W; Zhou L
Front Pharmacol; 2022; 13():924817. PubMed ID: 35754474
[TBL] [Abstract][Full Text] [Related]
14. The Transcriptomic Response of the Murine Thyroid Gland to Iodide Overload and the Role of the Nrf2 Antioxidant System.
Chartoumpekis DV; Ziros PG; Georgakopoulos-Soares I; Smith AAT; Marques AC; Ibberson M; A Kopp P; Habeos I; Trougakos IP; Khoo NKH; Sykiotis GP
Antioxidants (Basel); 2020 Sep; 9(9):. PubMed ID: 32961913
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of Keap1-Nrf2 signaling.
Guo Y; Yu S; Zhang C; Kong AN
Free Radic Biol Med; 2015 Nov; 88(Pt B):337-349. PubMed ID: 26117320
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis.
Yang JJ; Tao H; Hu W; Liu LP; Shi KH; Deng ZY; Li J
Cell Signal; 2014 Nov; 26(11):2381-9. PubMed ID: 25049078
[TBL] [Abstract][Full Text] [Related]
17. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.
Wong TF; Yoshinaga K; Monma Y; Ito K; Niikura H; Nagase S; Yamamoto M; Yaegashi N
Int J Gynecol Cancer; 2011 Nov; 21(8):1428-35. PubMed ID: 21897267
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the role of Nrf2/Keap1 pathway-associated novel mutations and gene expression on antioxidant status in patients with deep vein thrombosis.
Akin-Bali DF; Eroglu T; Ilk S; Egin Y; Kankilic T
Exp Ther Med; 2020 Aug; 20(2):868-881. PubMed ID: 32742329
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.
Hamada S; Shimosegawa T; Taguchi K; Nabeshima T; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G65-G74. PubMed ID: 28971839
[TBL] [Abstract][Full Text] [Related]
20. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
